Patient characteristics and responses to nivolumab
| . | Patient . | ||||
|---|---|---|---|---|---|
| 1 . | 2 . | 3 . | 4 . | 5 . | |
| Disease | Primary refractory PCNSL | Recurrent PCNSL | Recurrent PCNSL | Recurrent PCNSL | CNS recurrence of PTL |
| Symptoms at current presentation, KPS (%) | Subtle visual field deficit and cognitive changes; 70 | Cognitive changes; 80 | Nausea, vomiting, ataxia; 50 | Asymptomatic; 80 | Aphasia, impaired level of consciousness (LOC); 40 |
| Radiographic response | Complete response | Complete response* | Partial response | Complete response | Complete response† |
| Neurologic/clinical response, KPS (%) | Resolution of visual field deficit and cognitive changes; 90 | Resolution of cognitive changes; 80 | Resolution of nausea, vomiting and ataxia; 70 | Stable (asymptomatic); 80 | Resolution of aphasia and impaired LOC; 80 |
| Progression-free survival (mo) | 13+ | 17 | 17+ | 14 | 14+ |
| . | Patient . | ||||
|---|---|---|---|---|---|
| 1 . | 2 . | 3 . | 4 . | 5 . | |
| Disease | Primary refractory PCNSL | Recurrent PCNSL | Recurrent PCNSL | Recurrent PCNSL | CNS recurrence of PTL |
| Symptoms at current presentation, KPS (%) | Subtle visual field deficit and cognitive changes; 70 | Cognitive changes; 80 | Nausea, vomiting, ataxia; 50 | Asymptomatic; 80 | Aphasia, impaired level of consciousness (LOC); 40 |
| Radiographic response | Complete response | Complete response* | Partial response | Complete response | Complete response† |
| Neurologic/clinical response, KPS (%) | Resolution of visual field deficit and cognitive changes; 90 | Resolution of cognitive changes; 80 | Resolution of nausea, vomiting and ataxia; 70 | Stable (asymptomatic); 80 | Resolution of aphasia and impaired LOC; 80 |
| Progression-free survival (mo) | 13+ | 17 | 17+ | 14 | 14+ |
The patient was subsequently unable to get gadolinium contrast due to renal insufficiency. The radiographic complete response reflects complete resolution of the nonenhancing T2 signal change in the area of prior involvement.
The patient’s parenchymal and leptomeningeal disease completely responded to nivolumab therapy; persistent intraocular disease was treated with ocular radiation.